Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Last trade$0.9012
Day change-$0.0452 (-4.78%)
Day range$0.879 – $0.948
Volume285,131
Market cap$55M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$55.35M
Price / earnings
—
Price / book
70.87×
Price / sales
1.33×
EV / sales
-1.27×
EV / EBITDA
1.88×
Profitability
Earnings per share
-$0.51
Return on assets
-26.82%
Return on equity
-3,778.87%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
1.92×
Quick ratio
1.92×
Cash ratio
1.89×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$40.45M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for SPRO, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$258K
$41.3M
$5.44M
$14.19M
$5.87M
$15.04M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$258K
$41.3M
$5.44M
$14.19M
$5.87M
$15.04M
Selling, general and administrative
$3.72M
$6.49M
$4.89M
$4.3M
$4.17M
$5.88M
$6.82M
$7.06M
Research and development
$38.2M
$3.43M
$2.91M
$5.59M
$8.6M
$10.67M
$13.61M
$28.84M
Total operating expenses
$41.91M
$9.93M
$7.8M
$9.89M
$13.36M
$16.63M
$20.61M
$36.77M
Operating income
-$41.91M
-$9.93M
-$7.54M
$31.41M
-$7.92M
-$2.44M
-$14.73M
-$21.73M
Interest expense
-$3.28M
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$44.28M
-$9.55M
-$7.2M
$31.78M
-$7.38M
-$1.7M
-$13.87M
-$20.6M
Income taxes
$0
$0
$0
$261K
$0
$0
$0
$290K
Net income
-$44.28M
-$9.55M
-$7.2M
$31.52M
-$7.38M
-$1.7M
-$13.87M
-$20.89M
Net income attributable to common shareholders
-$44.28M
-$9.55M
-$7.2M
$31.52M
-$7.38M
-$1.7M
-$13.87M
-$20.89M
EBITDA
-$41.91M
-$9.93M
-$7.54M
$31.41M
-$7.33M
-$2.36M
-$14.56M
-$20.85M
Basic earnings per share
-$0.76
-$0.16
-$0.13
$0.56
-$0.13
-$0.03
-$0.25
-$0.38
Diluted earnings per share
-$0.76
-$0.16
-$0.13
$0.46
-$0.13
-$0.03
-$0.25
-$0.38
Recent news
Company coverage with links to the original publishers.
The complicated urinary tract infections (cUTI) market is expected to grow steadily through 2036, driven by rising antimicrobial resistance, increasing recurrent and hospital-acquired infections, and recent drug approvals. Key approvals include GSK/Spero Therapeutics' UTEBZI (oral antibiotic) and Wockhardt's ZAYNICH (intravenous antibiotic), both approved in 2026. Emerging therapies from companies like Venatorx Pharmaceuticals, Meiji Seika Pharma, and Locus Biosciences targeting multidrug-resistant Gram-negative bacteria are expected to further expand the market.
Spero Therapeutics and Innovent Biologics announced an exclusive license agreement for SP001 (IBI355), a third-generation anti-CD40L antibody. Spero receives global rights excluding Greater China, with potential milestone payments totaling approximately $1.1 billion plus tiered royalties. Spero plans to initiate a Phase 2 trial in IgG4-related disease in Q2 2027, while Innovent will pursue a Phase 2 trial in Sjögren's disease in China by early 2027.
GSK and Spero Therapeutics announced FDA approval of Utebzi (tebipenem pivoxil hydrobromide), the first oral carbapenem antibiotic for treating complicated urinary tract infections including pyelonephritis. The drug demonstrated non-inferiority to intravenous imipenem-cilastatin in Phase 3 trials and is expected to launch in the U.S. by end of 2026, offering an alternative to hospital-based IV treatments for the 3+ million Americans annually affected by cUTIs.
Spero Therapeutics granted 90,000 restricted stock unit awards to a new employee under their 2019 Inducement Equity Incentive Plan, with vesting occurring in four equal annual installments starting December 1, 2025.
Spero Therapeutics announced interim leadership changes, including the appointment of Esther Rajavelu as Interim President and CEO, and Frank Thomas as Chairman of the Board. The company also provided updates on the Phase 3 PIVOT-PO trial of Tebipenem HBr and its financial position.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.